Ritter Pharmaceuticals, Inc. (RTTR) Issues Earnings Results
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.14), Bloomberg Earnings reports.
Ritter Pharmaceuticals (RTTR) traded down 2.4604% during midday trading on Wednesday, reaching $0.3568. The company’s stock had a trading volume of 1,326,453 shares. The firm’s market cap is $5.26 million. The firm has a 50 day moving average price of $0.43 and a 200 day moving average price of $0.43. Ritter Pharmaceuticals has a one year low of $0.32 and a one year high of $3.75.
ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/01/ritter-pharmaceuticals-inc-rttr-issues-earnings-results.html.
A number of equities research analysts have weighed in on the company. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Tuesday, September 26th. Maxim Group restated a “hold” rating on shares of Ritter Pharmaceuticals in a research report on Friday, August 4th. HC Wainwright lowered their price target on Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research report on Monday, October 23rd. Finally, Chardan Capital lowered their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $2.92.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.